Humacyte Statistics

Total Valuation

Humacyte has a market cap or net worth of $366.08 million. The enterprise value is $385.75 million.

Market Cap	366.08M
Enterprise Value	385.75M

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025, before market open.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Humacyte has 155.12 million shares outstanding. The number of shares has increased by 18.75% in one year.

Current Share Class	155.12M
Shares Outstanding	155.12M
Shares Change (YoY)	+18.75%
Shares Change (QoQ)	+3.76%
Owned by Insiders (%)	7.40%
Owned by Institutions (%)	39.51%
Float	121.93M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	708.09
Forward PS	28.50
PB Ratio	10.16
P/TBV Ratio	10.16
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	746.12
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.68, with a Debt / Equity ratio of 2.29.

Current Ratio	3.68
Quick Ratio	3.16
Debt / Equity	2.29
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-10.61

Financial Efficiency

Return on equity (ROE) is -249.75% and return on invested capital (ROIC) is -62.70%.

Return on Equity (ROE)	-249.75%
Return on Assets (ROA)	-42.82%
Return on Invested Capital (ROIC)	-62.70%
Return on Capital Employed (ROCE)	-77.88%
Revenue Per Employee	$2,350
Profits Per Employee	-$363,818
Employee Count	220
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -61.87% in the last 52 weeks. The beta is 2.00, so Humacyte's price volatility has been higher than the market average.

Beta (5Y)	2.00
52-Week Price Change	-61.87%
50-Day Moving Average	1.94
200-Day Moving Average	3.81
Relative Strength Index (RSI)	51.35
Average Volume (20 Days)	4,178,267

Short Selling Information

The latest short interest is 31.80 million, so 20.50% of the outstanding shares have been sold short.

Short Interest	31.80M
Short Previous Month	30.35M
Short % of Shares Out	20.50%
Short % of Float	26.08%
Short Ratio (days to cover)	6.28

Income Statement

In the last 12 months, Humacyte had revenue of $517,000 and -$80.04 million in losses. Loss per share was -$0.65.

Revenue	517,000
Gross Profit	-82.38M
Operating Income	-111.00M
Pretax Income	-105.70M
Net Income	-80.04M
EBITDA	-103.77M
EBIT	-111.00M
Loss Per Share	-$0.65

Full Income Statement

Balance Sheet

The company has $62.85 million in cash and $82.51 million in debt, giving a net cash position of -$19.67 million or -$0.13 per share.

Cash & Cash Equivalents	62.85M
Total Debt	82.51M
Net Cash	-19.67M
Net Cash Per Share	-$0.13
Equity (Book Value)	36.04M
Book Value Per Share	0.23
Working Capital	53.68M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$99.38 million and capital expenditures -$1.41 million, giving a free cash flow of -$100.79 million.

Operating Cash Flow	-99.38M
Capital Expenditures	-1.41M
Free Cash Flow	-100.79M
FCF Per Share	-$0.65

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-21,470.79%
Pretax Margin	-15,022.44%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Humacyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.75%
Shareholder Yield	-18.75%
Earnings Yield	-21.86%
FCF Yield	-27.53%

Analyst Forecast

The average price target for Humacyte is $13.00, which is 450.85% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$13.00
Price Target Difference	450.85%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Humacyte has an Altman Z-Score of -4.43. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.43
Piotroski F-Score	n/a